0000899243-21-048894.txt : 20211217
0000899243-21-048894.hdr.sgml : 20211217
20211217202733
ACCESSION NUMBER: 0000899243-21-048894
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20211215
FILED AS OF DATE: 20211217
DATE AS OF CHANGE: 20211217
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Renger John
CENTRAL INDEX KEY: 0001830363
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39311
FILM NUMBER: 211503383
MAIL ADDRESS:
STREET 1: C/O CEREVEL THERAPEUTICS, INC.
STREET 2: 51 ASHTOR PLACE
CITY: NEW YORK
STATE: NY
ZIP: 10003
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Cerevel Therapeutics Holdings, Inc.
CENTRAL INDEX KEY: 0001805387
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 222 JACOBS STREET
STREET 2: SUITE 200
CITY: CAMBRIDGE
STATE: MA
ZIP: 02141
BUSINESS PHONE: 844-304-2048
MAIL ADDRESS:
STREET 1: 222 JACOBS STREET
STREET 2: SUITE 200
CITY: CAMBRIDGE
STATE: MA
ZIP: 02141
FORMER COMPANY:
FORMER CONFORMED NAME: ARYA Sciences Acquisition Corp II
DATE OF NAME CHANGE: 20200303
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2021-12-15
0
0001805387
Cerevel Therapeutics Holdings, Inc.
CERE
0001830363
Renger John
C/O CEREVEL THERAPEUTICS HOLDINGS, INC.
222 JACOBS STREET, SUITE 200
CAMBRIDGE
MA
02421
0
1
0
0
Chief Scientific Officer
Common Stock
2021-12-15
4
M
0
25000
3.50
A
26980
D
Common Stock
2021-12-15
4
S
0
25000
30.0179
D
1980
D
Common Stock
2021-12-16
4
M
0
5578
3.50
A
7558
D
Common Stock
2021-12-16
4
S
0
5578
32.50
D
1980
D
Common Stock
2021-12-17
4
M
0
7122
3.50
A
9102
D
Common Stock
2021-12-17
4
S
0
7122
32.50
D
1980
D
Stock Option (Right to Buy)
3.50
2021-12-15
4
M
0
25000
0.00
D
2029-04-02
Common Stock
25000
400875
D
Stock Option (Right to Buy)
3.50
2021-12-16
4
M
0
5578
0.00
D
2029-04-02
Common Stock
5578
395297
D
Stock Option (Right to Buy)
3.50
2017-12-17
4
M
0
7122
0.00
D
2029-04-02
Common Stock
7122
388175
D
The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan dated October 8, 2021 adopted by the Reporting Person.
Includes 1,980 shares acquired under the Issuer's Employee Stock Purchase Plan on May 28, 2021.
The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.00 to $30.13 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or to the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
25% of the shares subject to this option vested and became exercisable on April 8, 2020, with the remainder vesting in thirty-six (36) equal monthly installments thereafter.
/s/ Mark Bodenrader, as Attorney-in-Fact
2021-12-17